MIRAMAR, FL, June 09, 2022 (GLOBE NEWSWIRE) — Stemtech Corporation (“Stemtech”) (STEK, Financial), an innovative nutraceutical company and pioneer in ADVANCELLS stem cell nutrition, today announced that Ana Groenewold, an Independent Business Partner from Mexico, attained the senior rank of Chairman’s Club Director in May. This coincided with the 90-day GLD RSH promotional period where sales and recruitment hit an all-time high in May 2022.
“Ana is a very dedicated and determined individual who set her sights on becoming Chairman’s Club Director and enthusiastically achieved this high rank in May,” said John W. Meyer, President and COO of Stemtech. Corporation. “Stemtech is proud of Ana’s accomplishments and applauds her efforts to share the benefits of our great products and business opportunities,” continued Meyer. “President and CEO Charles Arnold and I were very happy to call Ana and congratulate her on her success,” Meyer said. Ana Groenewold has worked with so many people, including Stemtech’s General Manager for Latin Markets, Alejandro Carrillo, who expresses his admiration for Ana’s drive to succeed.
Ana commented, “I wanted a project with the potential to change the world! 9 years ago, I discovered Stemtech and since then, the passion was born in me not to stop a single day! I love Stemtech, I love my life, I love my awesome, awesome team!
About Stemtech Corporation
Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations of its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 to 2015 , Stemtech International, Inc. , has been recognized four times on the Inc. 5000 fastest growing companies listing. In 2018, the Company underwent an extensive management reorganization and continued operations under new management. Stemtech specializes in creating products and formulas protected by patents in the United States and certain international markets. The company’s patented formulas promote the release, circulation and migration of the body’s adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3™Stemflo®MigraStem®OraStem® (Oral Health Care) and D-Fuze™ (EMF Blocker). Its products are all-natural and herbal and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit www.stemtech.com.
Forward-looking statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements identified by words such as “believes ”, “expects”, “plans”, “estimates”, “intends”, “plans”, “target”, “projects” and similar expressions. The statements in this release are based on the current beliefs and expectations of the management of our company and are subject to significant risks and uncertainties. Actual results may differ from those set forth in forward-looking statements. Many factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, challenges inherent in new product development initiatives, the effect any competing products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is needed to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any government review of our products or practices, and other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our last 10-K filed April 1, 2022. We undertake no obligation to update any forward-looking statement or information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation that are tolerated by the Company must come from the Company itself and bear our name as the source.
For more information, contact:
Investors: Frank J. Pena, 908-675-0581, [email protected]
Attachment
